Clinical Trials Browser

zimberelimab × Gastrointestinal × 90 days × Clear all

NCT05568095 2026-03-04

STAR-221

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT04104672 2026-02-27

ARC-8

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05329766 2026-02-27

EDGE-Gastric

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT05891171 2026-02-27

ARC-25

Phase 1 Active not recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05419479 2026-02-24

Switch Maintenance in Pancreatic

Phase 1/2 Suspended

Gastrointestinal

Pancreatic Neoplasms

NCT06048133 2026-01-23

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Phase 2 Recruiting

Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

NCT07283848 2025-12-26

Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Stomach Neoplasms